STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
CRNX CRINETICS PHARMACEUTICALS INCORPORATED StockScouter® Report
3
StockScouter® Score
CRINETICS PHARMACEUTICALS INCORPORATED, a mid cap company in the healthcare sector, is expected to perform in line with the market over the next six months with higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- The multi-period measure of relative price change and consistency is well above average. Positive
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- One or more analysts has modestly decreased quarterly earnings estimates for CRNX. Negative
- Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
D
D
F
A